Ovid Therapeutics (OVID) Cash from Operations (2016 - 2026)
Ovid Therapeutics (OVID) posted Cash from Operations of 13899000.0 for Q1 2026, down 33.98% on a QoQ basis from 10374000.0 in Q4 2025, and down 35.2% year-over-year from 21450490.92 in Q1 2025.
Ovid Therapeutics (OVID) Cash from Operations (2016 - 2026) Analysis & Trends
Ovid Therapeutics' Cash from Operations history runs 11 years deep, the most recent figure standing at 13899000.0 for Q1 2026.
- Quarterly Cash from Operations fell 35.2% year-over-year to 13899000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 41919000.0 (up 15.4% YoY) and the FY2025 annual result came in at 38300000.0, up 31.55% from the prior year.
- Cash from Operations was 13899000.0 for Q1 2026 at Ovid Therapeutics, down from 10374000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 4820000.0 in Q2 2025 and bottomed at 20086419.0 in Q1 2022.
- A 5-year average of 12303713.35 and a median of 12112000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 112.48% — and 2025, when it soared 66.19%.
- Ovid Therapeutics' Cash from Operations stood at 9175732.0 in 2022, then slipped by 29.81% to 11911000.0 in 2023, then climbed by 15.98% to 10008000.0 in 2024, then fell by 3.66% to 10374000.0 in 2025, then sank by 33.98% to 13899000.0 in 2026.
- Business Quant data shows OVID's Cash from Operations at 13899000.0 in Q1 2026, 10374000.0 in Q4 2025, and 12826000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.17 Mn |
| 10 | Ovid Therapeutics | 118.66 Mn | -36.86 Mn | - | -13.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.90 Mn |
| Mar 31, 2026 | -13.90 Mn |
| Dec 31, 2025 | -10.37 Mn |
| Dec 31, 2025 | -10.37 Mn |
| Sep 30, 2025 | -12.83 Mn |
| Sep 30, 2025 | -12.83 Mn |
| Jun 30, 2025 | -4.82 Mn |
| Jun 30, 2025 | -4.82 Mn |
| Mar 31, 2025 | -10.28 Mn |
| Mar 31, 2025 | -10.28 Mn |
| Dec 31, 2024 | -10.01 Mn |
| Dec 31, 2024 | -10.01 Mn |
| Sep 30, 2024 | -15.01 Mn |
| Sep 30, 2024 | -15.01 Mn |
| Jun 30, 2024 | -14.26 Mn |
| Jun 30, 2024 | -14.26 Mn |
| Mar 31, 2024 | -16.69 Mn |
| Mar 31, 2024 | -16.69 Mn |
| Dec 31, 2023 | -11.91 Mn |
| Dec 31, 2023 | -11.91 Mn |